IMPORTANCE Congenital myasthenic syndromes (CMS) are heterogeneous disorders. Defining the phenotypic features, genetic basis, and pathomechanisms of a CMS is relevant to prognosis, genetic counseling, and therapy.
vated MuSK, in concert with DOK7 and other postsynaptic proteins, acts on rapsyn to concentrate the acetylcholine receptor (AChR) in the postsynaptic membrane and promotes postsynaptic gene expression and differentiation. Clustered LRP4 also enhances presynaptic differentiation. 3 Several reports have described congenital myasthenic syndromes (CMSs) caused by mutations in agrin [4] [5] [6] and MuSK, [7] [8] [9] [10] [11] but only 1 report has described mutations in LRP4. 12 This was the case of a 14-year-old girl with moderately severe fatigable limb-girdle weakness, dysplastic synaptic contacts, borderline end-plate (EP) AChR deficiency, smaller-than-normal individual EP regions, but no demonstrable defect of neuromuscular transmission at intercostal muscle EPs. The patient's weakness continued to progress, and by 24 years of age, she was barely able to walk. Herein we describe 2 young adult sisters with LRP4-related myasthenia caused by a novel homozygous LRP4 mutation. Intercostal muscle studies of the older sister reveal structurally and functionally abnormal EPs and EP AChR deficiency. Expression studies indicate that the mutant protein hinders LRP4 from binding to, activating, and phosphorylating MuSK.
Methods

Participants
All human studies were approved by the institutional review board of the Mayo Clinic in Rochester, Minnesota, and the 2 sisters (ie, patients) and 15 historical control participants provided written informed consent to participate in the studies. Intercostal muscle was obtained from the 15 historical control participants during chest surgery for unrelated diseases.
Genetic Analysis
Sanger sequencing for mutations in genes known to cause limbgirdle CMS (namely, RAPSN, DOK7, GFPT1, and DPAGT1) gave negative results. Next, exome sequencing of genomic DNA from both siblings was performed at the Mayo Clinic. The identified putative variants were scrutinized with Ingenuity Variant Analysis software (Qiagen). Variants at intergenic and intronic sites, and genes not expressed in skeletal muscle or the spinal cord based on the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/), were excluded. The identified mutation was confirmed by Sanger sequencing of the family. Nucleotides of LRP4 complementary DNA (cDNA) were numbered according to GeneBank accession number NM_002334.3.
To determine whether an identified nucleotide variant caused abnormal splicing, we isolated cDNA from the muscle specimens obtained from control participants and the 2 patients. To detect any alternative transcript, we amplified the cDNA from exons 25 to 29 and exons 26 to 28 with primers designed for the cDNA of the 2 patients and 2 control participants.
Structural Studies
Intercostal and serratus anterior muscle specimens were obtained from the older sister and from control participants without muscle disease undergoing thoracic surgery. Cryosections were used to colocalize the AChR and acetylcholinesterase as previously described. 13 End plates were localized for electron microscopy 14 and quantitatively analyzed 15 by established methods. Peroxidase-labeled α-bungarotoxin was used for the ultrastructural localization of AChR. 16 The number of AChRs per EP was measured with iodine 125-labeled α-bungarotoxin. 17 
In Vitro Electrophysiology Studies
Quantitative analysis of single EP regions was done for all 15 control participants and microelectrode studies of neuromuscular transmission and α-bgt binding sites per EP was conducted for 13 control participants. Intracellular microelectrode studies were performed on an intercostal muscle specimen obtained from the 34-year-old sister (patient 1). The amplitude of the miniature EP potential (MEPP) and the quantal content of the EPP (m) were determined as previously described.
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Plasmids
We used the following previously constructed plasmids: (1) fulllength human LRP4 cDNA for the luciferase assay and cell surface binding assays; (2) mouse Musk cDNA for luciferase assay; (3) the extracellular domain of mouse Musk cDNA and a fraction (amino acids 1141-1937) of rat Agrn cDNA, both of which were fused to an myc-tag and alkaline phosphatase (MuSKectmycAP and agrin-mycAP) for cell surface binding assay; and (4) human MUSK cDNA with a flag-tag at the N-terminal end for coimmunoprecipitation assay. Mutant LRP4 plasmid carrying p.Glu1233Ala was generated by the QuikChange SiteDirected Mutagenesis kit (Stratagene). 12 The ATF2-luciferase (ATF2-luc) reporter 12 and the phRL-TK Renilla luciferase vector (Promega) were used for the luciferase reporter assay.
Cell Cultures
HEK293 and COS7 cells were cultured in the Dulbecco Modified Eagle Medium supplemented with 10% fetal calf serum, and transfected with FuGENE 6 transfection reagent (Roche). The agrin-mycAP and MuSKect-mycAP proteins were produced as previously described. 12 Recombinant rat C-terminal agrin (10 ng/mL; R&D Systems) was used for agrin treatment, except for the cell-binding assays.
Luciferase Assays
We used an ATF2-luc reporter to monitor MuSK activation. The basis for this approach is that agrin induces JNK activation in myotubes 21 and that a previous report 22 has demonstrated in-
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HEK293 cells were transfected with ATF2-luc and phRL-TK along with the MUSK cDNA and the LRP4 cDNA. Cells were cultured for 24 hours in a 96-well plate with or without 10 ng/mL of agrin in the medium. Cells were lysed with the Passive Lysis Buffer (Promega) and assayed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega). Each experiment was performed in triplicate.
Western Blotting
HEK293 cells transfected with MuSK and LRP4 plasmids were cultured for 24 hours in the presence of 10 ng/mL of agrin, as previously described. 12 The primary antibodies were mouse monoclonal anti-FLAG M2 (Sigma-Aldrich; F3165, dilution 1:4000), anti-β-actin (Santa Cruz Biotechnology; sc-47778, dilution 1:200), and the goat polyclonal anti-LRP4 (Abcam; ab85697, dilution 1:1000). The secondary antibodies were goat antimouse IgG (GE Healthcare; NA931V, dilution 1:6000) and mouse antigoat IgG (Santa Cruz Biotechnology; sc-2345, dilution 1:6000) conjugated to horseradish peroxidase.
Biotinylation Assay
HEK293 cells transfected with plasmids harboring wild-type LRP4 or its Glu1233Ala mutant were cultured for 48 hours. Cell surface proteins were isolated by biotinylating the cell surface proteins and precipitating the bound proteins with streptavidin beads, as previously described.
12
Results
Clinical Data
Two young adult sisters with CMS (patient 1 in her mid-30s and patient 2 in her early 20s) who were born to nonconsanguineous parents, were investigated. Their parents and other siblings are unaffected. Patient 1 was born after normal gestation and delivery. months. Developmental milestones (sitting and walking) were slightly delayed; after beginning to walk, she fell frequently. As a young child, she had mild difficulty chewing and swallowing. She never climbed steps or kept up with her peers in physical activities. Her weakness worsened around her menses. In her teens, she could only walk a short distance with support and became dependent on a wheelchair. On initial examination, she could barely rise from the sitting position without support, and her gait was waddling, hyperlordotic, and intoeing. Her weakness was confined to the axial and limb muscles with selective severe involvement of the dorsal forearm muscles. Her tendon reflexes were hypoactive. Her vital capacity was reduced to 49%, and the maximal inspiratory and expiratory pressures were reduced to 43% and 22% of normal, respectively. Repetitive nerve stimulation at 2 Hz revealed a decremental response of 37% in the trapezius and of 14% in facial muscles of the fourth compared with the first evoked compound muscle action potential (CMAP) (normal, <10%). Repetitive CMAPs, typical of the slowchannel myasthenic syndrome or EP acetylcholinesterase deficiency, 23 were absent. Brief strenuous exercise did not appreciably improve the decremental response or potentiate the first evoked CMAP as in the CMS-caused synaptotagmin-2 deficiency, 24 in some patients harboring mutations in agrin, 6 or in the Lambert-Eaton syndrome. 23 Needle electromyographic studies of multiple muscles revealed an increased proportion of short-duration, polyphasic motor unit potentials without spontaneous electrical activity, a common finding in myasthenic disorders owing to a variable proportion of muscle fibers in motor units failing to generate an action potential. After treatment with 4 mg of albuterol sulfate twice daily for 1 week, patient 1 rose up from the sitting position 10 times without support, and the electromyographic decrement in her trapezius muscle decreased to 25%. One week later, she climbed 10 steps, walked 450 m (500 yd), and was able to groom herself independently. Additional treatment with pyridostigmine bromide or 3,4-diaminopyridine made her weaker and had to be discontinued.
Patient 2 appeared normal at birth and during infancy. She walked at a developmentally appropriate age but never learned to run or jump, found it difficult to climb steps, and could not keep up with her peers in physical activities. By late adolescence, her arm-elevation time was 22 seconds, and her gait was lordotic and waddling; she required assistance to rise from a sitting position and could climb only 20 steps before having to rest. There was mild weakness of the cervical and proximal arm muscles and mild to moderately severe weakness of the hip girdle muscles. Her tendon reflexes were hypoactive. Respiratory function tests showed that her vital capacity was reduced to 68% and that her maximal inspiratory and expiratory pressures were reduced to 39% and 47% of normal, respectively. After treatment with 4 mg of albuterol twice daily for 2 weeks, her arm and cervical muscles were of normal strength, her arm-elevation time was 60 seconds, and she could climb 44 steps before having to rest. Additional treatment with 60 mg of pyridostigmine twice daily over the next 2 years neither improved nor worsened her condition. A needle electromyographic examination suggested a mild proximal myopathy. After receiving albuterol for 2 years, repetitive stimulation of multiple muscles revealed no significant decrement of the evoked CMAP.
Structural Studies
Structural studies were performed in patient 1. Light microcopy revealed markedly diminished EP size. In transverse frozen sections reacted for acetylcholinesterase, the median length of 34 EPs was 7.2 μm ( Figure 1A , B, E, and F); the median length of 69 EPs of 3 control participants was 21.3 μm (P < .001, determined by the use of the rank sum test) (Figure 1C, D, G, and H) . Paired fluorescence localization studies revealed reduced synaptic expression of acetylcholinesterase and of the AChR in the EPs of patient 1 ( Figure 1E and F) compared with the EPs in the 3 control participants ( Figure 1G and H) .
Qualitative inspection of 15 EP regions revealed 7 postsynaptic regions unoccupied or partially occupied by the nerve terminal ( Figure 1K and L) and 2 regions displaying degenerating junctional folds ( Figure 1K ). In contrast, at 157 EP regions of control participants, only 15 postsynaptic regions were unoccupied by the nerve terminal (P < .001, determined by use of the rank sum test), and only 6 postsynaptic regions displayed degenerating folds (P < .03, determined by use of the z score). Most postsynaptic regions had poorly developed junctional folds ( Figure 1I and J), and a single nerve terminal was degenerating ( Figure 1K ). The postsynaptic reaction for AChR, revealed by peroxidase-labeled α-bungarotoxin, was attenuated ( Figure 1J ). At the light microscopic level, the intercostal muscle specimen showed a single-target formation and small focal decreases of enzyme activity. Consistent with this, at the electron microscopic level, occasional muscle fibers displayed focal myofibrillar degeneration ( Figure 1M ) that is likely secondary to functional denervation. Morphometric analysis revealed that the size of the nerve terminal was not significantly different from normal but that the postsynaptic area was reduced by 33% (ie, 67% of normal) and that the postsynaptic membrane density was reduced by 50% (ie, 50% of normal) ( Table 1 ).
In Vitro Analysis of Neuromuscular Transmission
The evoked EPPs were subthreshold to trigger action potentials and were recorded without curare. The mean values for the EPP amplitude, the quantal content of the EPP (m), and the amplitude of the MEPP derived from the quantal component of the EPP were reduced to 16%, 40%, and 43%, respectively, of the corresponding mean values for the control participants. The mean number of AChRs per EP, determined from the number of α-bungarotoxin binding sites, was decreased to 25% of the mean number for the control participants ( Table 2) .
Mutation Analysis
Whole-exome sequencing in both patients (confirmed by Sanger sequencing) revealed a novel homozygous p.Glu1233Ala (c.3698A>C) mutation in exon 26 ( Figure 2) . The mutated residue is positioned at the edge of the third β-propeller domain of LRP4 and close to the conserved YWTD motif important for β-sheet formation. The unaffected brother and the mother are heterozygous for the mutation. Because the A>C variant is the penultimate nucleotide of exon 26 and because MutationTaster predicts it to alter splicing, we isolated cDNA from the patient's intercostal and serratus anterior muscles and amplified the segment, including exon 26 by 2 different sets of primers. In both specimens, the mutant residue was homozygous, and there was no evidence for abnormal splicing. stream of JNK to induce clustering of AChRs. 12, 27 To investigate the effect of the Glu1233Ala mutation on this signaling pathway, we used a JNK-responsive ATF2-luc reporter that specifically monitors MuSK-dependent stimulation in transfected HEK293 cells. 27 When LRP4 and MuSK are overexpressed, limited ATF2 activation occurs even in the absence of agrin. 12 The addition of agrin to this system further enhances ATF2 activation by wild-type LRP4, whereas activation of ATF2 by mutant LRP4 is markedly attenuated ( Figure 3A) . We found that both the previously reported Glu1233Lys mutation 12 ( Figure 3B ) and the currently identified Glu1233Ala mutation ( Figure 3A ) compromise ATF2 activation, but the activation is consistently lower with Glu1233Ala than with Glu1233Lys. In another experiment using HEK293 cells, we examined the effects of wild-type and mutant LRP4 on MuSK phosphorylation that occurs during the assembly of the agrin-LRP4-MuSK complex. Consistent with its effects on MuSK signaling activity, mutant LRP4 compromises agrin-enhanced MuSK phosphorylation ( Figure 3C ). Both experiments support the notion that Glu1233Ala in LRP4 compromises agrin-mediated activation of MuSK.
MuSK and agrin bind to different extracellular residues of LRP4. 3 We therefore examined the binding of MuSK and agrin to mutant and wild-type LRP4 expressed on the surface of COS cells. We first confirmed that both wild-type and mutant LRP4
are similarly expressed on the plasma membrane by use of the biotinylation assay ( Figure 3D ). We then overlaid recombinant human MuSKect-AP and recombinant human neural agrin-AP on COS cells expressing LRP4. Measurement of alkaline phosphatase activity revealed that MuSK and agrin bind efficiently to wild-type LRP4 but not to mutant LRP4 ( Figure 3E ). Thus, all 3 experiments indicate that Glu1233Ala in LRP4 inhibits agrinmediated upregulation of MuSK signaling.
Discussion
The 2 sisters described in this report harbor a homozygous p.Glu1233Ala mutation in the third propeller domain of LRP4 that binds to and activates MuSK. An intercostal muscle biopsy of the older sister revealed very small EPs with poorly developed postsynaptic regions, and postsynaptic regions that were degenerating or denuded of their nerve terminal. The amplitude of the EPP was reduced to 16% of normal owing to the combined decrease of the quantal content of the EPP and of the MEPP amplitude ( Table 2 ). The decreased amplitude of the MEPP can be attributed to decreased input resistance of the EP owing to simplification of the postsynaptic membrane, as well as the attenuated expression of AChRs on the remaining junctional folds. The decreased quantal content of the EPP is adequately explained by the small size of individual EPs, and hence of the total number of synaptic vesicles available for release by nerve impulse. Thus, the observed structural and electrophysiologic abnormalities are consistent with an abrogated role played by LRP4 in the development and maintenance of the neuromuscular junction. mutant protein in the 2 sisters in this study revealed impaired LRP4 binding to, activating, and phosphorylating MuSK. The reason for the much milder clinical, structural, and electrophysiologic abnormalities observed in the first identified patient with LRP4-related myasthenia compared with the patients described in this report remains unknown. We initially attributed the milder findings in the first reported patient to 
